Stimulatory responses of 40 patients with bone [33] and soft tissue [7] sarcomas to autologous tumor cells were correlated with clinical data and prognosis. Although conclusive judgments for individual patients cannot be made, some general features emerge: patients with stimulation indices > 1.5 have a 50% relapse-free interval after surgery of 22 months, patients with indices below 1.5 have a 50 % relapse-free interval of 5 months. 7 out of 10 responder patients are tumor-free 1 year after surgery as compared to 5 out of 19 (26%) of non-responder patients (p < 0.05). Remoral of the tumor is followed by an increase in the stimulatory response and by the disappearance of blocking serum factors in patients with favourable prognosis. Responses return to baseline levels in tumor free patients 9–12 months after surgery. The results suggest that tumor-associated immune responses play a role in the development of human sarcomas. In addition, 47 lymphocyte samples of 25 patients were tested for stimulation by autologous tumor cells and for cell-mediated cytotoxicity against allogeneic sarcoma cell lines. Similar results were obtained in both test systems when pre-therapy lymphocytes
📖 افتح في inklap 🔗 DOI 📮 اطلب بحثاً